A roundtable discussion of aromatase inhibitors as therapy for breast cancer

D. Craig Allred, Michael Baum, Aman U. Buzdar*, Robert W. Carlson, Mitchell Dowsett, Richard M. Elledge, William J. Gradishar, Generosa Grana, Anthony Howell, Eleftherios P. Mamounas

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


This article summarizes the conclusions of a meeting of diverse breast cancer experts who discussed issues, controversies, and new clinical trial results relevant to the use of aromatase inhibitors for treating postmenopausal women with breast cancer. The new generation of aromatase inhibitors (anastrozole, letrozole, exemestane) have largely replaced megestrol acetate as a second-line therapy in postmenopausal women with hormone-responsive advanced breast cancer. In addition, anastrozole and letrozole have been shown to be superior to tamoxifen for first-line therapy. Finally, recent results suggest that anastrozole may be superior to tamoxifen as adjuvant therapy for early stage disease in postmenopausal women with hormone-responsive disease.

Original languageEnglish (US)
Pages (from-to)213-222
Number of pages10
JournalBreast Journal
Issue number3
StatePublished - May 2003


  • Anastrozole
  • Aromatase inhibitor
  • Breast cancer
  • Estrogen receptor
  • Exemestane
  • Letrozole
  • Postmenopausal

ASJC Scopus subject areas

  • Internal Medicine
  • Surgery
  • Oncology


Dive into the research topics of 'A roundtable discussion of aromatase inhibitors as therapy for breast cancer'. Together they form a unique fingerprint.

Cite this